Gain or Amplification of Chromosome 1q Mediate Multiple Myeloma Resistant to Xpo-1 Inhibitor Selinexor Via Transcription Factor ETV3

被引：0
|
作者：
Gu, Huiyao [1 ]
Zhong, Yi [1 ]
Zhang, Enfan [2 ]
Cao, Liqin [3 ]
Cai, Zhen [4 ]
He, Jingsong [5 ]
机构：
[1] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Bone Marrow Transplantat Ctr,Dept Hematol, Hangzhou, Peoples R China
[2] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Bone Marrow Transplantat Ctr, Hangzhou, Peoples R China
[3] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Hangzhou, Peoples R China
[4] Zhejiang Univ, Affiliated Hosp 1, Bone Marrow Transplantat Ctr, Sch Med, Hangzhou, Peoples R China
[5] Zhejiang Univ, Affiliated Hosp 1, Dept Bone Marrow Transplantat Ctr, Sch Med, Hangzhou, Peoples R China
来源：
BLOOD | 2023年 / 142卷
关键词：
ETV3; multiple myeloma; Gain or amplification of chromosome 1q; selinexor;
D O I：
10.1182/blood-2023-184720
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 39 条
  • [31] Gain of Chromosome 1q Portends Worse Prognosis in Multiple Myeloma Patients Treated with Novel Agent Based Induction Regimens Even after Autologous Transplantation
    Shah, Gunjan L.
    Landry, Chrystal
    Londono, Dory
    Devlin, Sean
    Kosuri, Satyajit
    Lesokhin, Alexander M.
    Lendvai, Nikoletta
    Hassoun, Hani
    Chung, David J.
    Koehne, Guenther
    Jhanwar, Suresh
    Landgren, Ola
    Landau, Heather
    Giralt, Sergio
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (02) : S203 - S204
  • [32] The adverse impact of a gain in chromosome 1q on the prognosis of multiple myeloma treated with bortezomib-based regimens: A retrospective single-center study in China
    Chen, Qingxiao
    Han, Xiaoyan
    Zheng, Gaofeng
    Yang, Yang
    Li, Yi
    Zhang, Enfan
    Yang, Li
    Dong, Mengmeng
    He, Donghua
    He, Jingsong
    Cai, Zhen
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [33] Gene Expression and Transcription Factor (TF) Activation Profiling Identifies Suppression of Multiple Myeloma (MM) Cell Survival and Chemoresistance Pathways By Inhibition of XPO1/CRM1-Dependent Nuclear Export with Selinexor
    Rosebeck, Shaun
    Alonge, Mattina
    Jasielec, Jagoda
    Mayampurath, Anoop
    Volchenboum, Samuel L.
    Shacham, Sharon
    Kauffman, Michael
    Jakubowiak, Andrzej
    BLOOD, 2014, 124 (21)
  • [34] Chromosome 1q21 gain is an adverse prognostic factor for newly diagnosed multiple myeloma patients treated with bortezomib-based regimens
    Liu, Xiao
    Jia, Shuangshuang
    Chu, Yuping
    Tian, Biao
    Gao, Yaya
    Zhang, Chunyan
    Zheng, Yanhua
    Jia, Weijing
    Liu, Xiangxiang
    Yuan, Ruifeng
    Zhang, Na
    Feng, Juan
    Dong, Hongjuan
    Xin, Xiaoli
    Cao, Zhengcong
    Tang, Hailong
    Chang, Ziwei
    Gao, Guangxun
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [35] The combination of complement 1q and its receptor gC1qR could promote the proliferation of plasma cells through IGF2BP3 in multiple myeloma patients with 1q21 amplification
    Xu, Jiadai
    Liu, Peng
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E100 - E101
  • [36] Concomitant deletion of the short arm (Del 1p13.3) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma
    Mohan, Meera
    Gong, Zimu
    Ashby, Timothy Cody
    Al Hadidi, Samer
    Thanendrarajan, Sharmilan
    Schinke, Carolina
    Alapat, Daisy
    Shaughnessy Jr, John D. D.
    Zhan, Fenghuang
    van Rhee, Frits
    Sawyer, Jeffery R.
    Tian, Erming
    Zangari, Maurizio
    CANCER, 2023, 129 (16) : 2491 - 2498
  • [37] 1q21 amplification with additional genetic abnormalities but not isolated 1q21 gain is a negative prognostic factor in newly diagnosed patients with multiple myeloma treated with thalidomide-based regimens
    Grzasko, Norbert
    Hus, Marek
    Chocholska, Sylwia
    Pluta, Andrzej
    Hajek, Roman
    Dmoszynska, Anna
    LEUKEMIA & LYMPHOMA, 2012, 53 (12) : 2500 - 2503
  • [38] Daratumumab in high-risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome
    Mohan, Meera
    Weinhold, Niels
    Schinke, Carolina
    Thanedrarajan, Sharmilan
    Rasche, Leo
    Sawyer, Jeffrey R.
    Tian, Erming
    van Rhee, Frits
    Zangari, Maurizio
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 (01) : 67 - 71
  • [39] HIV-1 protease inhibitor induces growth arrest and apoptosis of human multiple myeloma cells via inactivation of signal transducer and activator of transcription 3 and extracellular signal-regulated kinase 1/2
    Ikezoe, T
    Saito, T
    Bandobashi, K
    Yang, Y
    Koeffler, HP
    Taguchi, H
    MOLECULAR CANCER THERAPEUTICS, 2004, 3 (04) : 473 - 479
1234